Clinical Trial

An Integrated Radio-immunological Approach

Study acronym: IMMUNO-IMAGING
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-24; most recent amendment 2026-01-22.
Status change: Recruiting → Active, Not Recruiting 2026-01-22
Trial Details
NCT Number NCT05267509
Lead Sponsor Istituto Oncologico Veneto IRCCS
Collaborators: Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliera di Padova
Conditions Glioma, Malignant
Enrollment 31 participants
Start Date 2022-02-23
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-23